Calidi Biotherapeutics, Inc. (CLDI) shareholders
Close on Nov 17, 2026Market cap $1.45MP/E –Yield –
Ownership
Who owns Calidi Biotherapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kessler Judd S | 3,729,842 | 5.00% | 13D (active) | May 1, 2024 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 3,359,661 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Funicular Funds, LP Joint filing with Cable Car Capital LLC (9.99%), Jacob Ma-Weaver (9.99%) | 897,241 | 9.99% | 13G (passive) | Sep 4, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Santidrian Antonio Fernandez | Chief Scientific Officer | 327,788 | Aug 19, 2026 |
| Eric E. Poma | Chief Executive Officer | 25,000 | Aug 19, 2026 |
| Andrew C. Jackson | Chief Financial Officer | 2,500 | Aug 19, 2026 |
| James A. Schoeneck | Director | 84,514 | Aug 19, 2026 |
| Alan R. Stewart | Director | 28,976 | Aug 19, 2026 |
| Corazon (Corsee) D. Sanders | Director | – | Aug 19, 2026 |
| Scott Leftwich | Director | 146,631 | Aug 19, 2026 |
| George Peoples | Director | – | Aug 19, 2026 |
| Allan Camaisa | Director | 143,664 | Dec 16, 2025 |
| Alternative Strategies LLC Lincoln | 10% owner | 730,000 | Aug 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Allan Camaisa Director | Dec 12, 2025 | Sale | −850 | $1.46 | $1.24K | 76,952 |
| Andrew C. Jackson Chief Financial Officer | Aug 21, 2025 | Buy | +2,500 | $2.00 | $5.00K | 2,500 |
| James A. Schoeneck Director | Aug 21, 2025 | Buy | +75,000 | $2.00 | $150.00K | 76,134 |
| Scott Leftwich Director | Aug 21, 2025 | Buy | +125,000 | $2.00 | $250.00K | 130,650 |
| Eric E. Poma Chief Executive Officer, Director | Aug 21, 2025 | Buy | +25,000 | $2.00 | $50.00K | 25,000 |
| Alan R. Stewart Director | Dec 31, 2024 | Award | +12,771 | – | – | 28,976 |
| Scott Leftwich Director | Dec 31, 2024 | Award | +11,684 | – | – | 67,774 |
| Allan Camaisa CEO and Chairman of the Board, Director | Dec 17, 2024 | Sale | −10,000 | $1.62 | $16.20K | 66,712 |
| Allan Camaisa CEO and Chairman of the Board, Director, 10% owner | Sep 26, 2024 | Award | +70,155 | $1.15 | $80.68K | 76,712 |
| Scott Leftwich Director | Jun 28, 2024 | Award | +67,187 | – | – | 560,873 |
| James A. Schoeneck Director | Jun 28, 2024 | Award | +79,687 | – | – | 1,071,781 |
| Alan R. Stewart Director | Jun 28, 2024 | Award | +73,437 | – | – | 154,087 |
| James A. Schoeneck Director | Jun 3, 2024 | Option exercise | +173,000 | $0.20 | $34.60K | 588,887 |
| James A. Schoeneck Director | Jun 3, 2024 | Option exercise | +375,000 | $0.20 | $75.00K | 963,887 |
| James A. Schoeneck Director | Apr 18, 2024 | Award | +375,000 | $0.40 | $150.00K | 415,887 |
| James A. Schoeneck Director | Mar 29, 2024 | Award | +28,207 | – | – | 992,094 |
| Alan R. Stewart Director | Mar 29, 2024 | Award | +25,995 | – | – | 80,650 |
| Scott Leftwich Director | Mar 29, 2024 | Award | +23,783 | – | – | 493,686 |
| Alan R. Stewart Director | Dec 21, 2023 | Award | +7,282 | $1.80 | $13.11K | 54,655 |
| Scott Leftwich Director | Dec 21, 2023 | Award | +8,958 | $1.80 | $16.12K | 469,903 |
| Alfonso G. Zulueta Director | Dec 21, 2023 | Award | +5,644 | $1.80 | $10.16K | 133,301 |
| James A. Schoeneck Director | Dec 21, 2023 | Award | +10,625 | $1.80 | $19.13K | 27,872 |
| Thomas A. Vecchiolla Director | Dec 21, 2023 | Award | +7,709 | $1.80 | $13.88K | 365,105 |
| Thomas A. Vecchiolla Director | Sep 12, 2023 | Conversion | +6,000 | – | – | 6,000 |
| FLAG Sponsor Manager, LLC 10% owner | Sep 12, 2023 | Conversion | +1,931,852 | – | – | 1,931,852 |
| Bay Capital Management LP Hudson 10% owner | Sep 12, 2023 | Other | −500,000 | $10.49 | $5.25M | 0 |
| Asset Management Partners Inc. Polar 10% owner | Oct 19, 2022 | Sale | −36,200 | $9.90 | $358.38K | 412,800 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Calidi Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 56,182 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?